NDA 217180 · Incyte Corp
Jakafi Xr
Ruxolitinib Phosphate · Oral · Kinase Inhibitor; Janus Kinase Inhibitor
OrphanLast checked: Nov 20, 2026Latest source record: Jul 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
May 1, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
453
74 Phase 3, 109 recruiting
FAERS reports
10,697
10,364 serious, 2,687 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 20, 2026.
JAKAFI/JAKAFI XR is a kinase inhibitor indicated for treatment of: intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults. ( 1.1 ) polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea. ( 1.2 ) steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. ( 1.3 ) chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. ( 1.4 ) 1.1 Myelofibrosis JAKAFI/JAKAFI XR is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF in adults. 1.2 Polycythemia Vera JAKAFI/JAKAFI XR is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea. 1.3 Acute Graft-Versus-Host Disease JAKAFI/JAKAFI XR is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older. 1.4 Chronic Graft-Versus-Host Disease JAKAFI/JAKAFI XR is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Mechanism: Ruxolitinib, a kinase inhibitor, inhibits Janus Associated Kinases (JAKs), JAK1 and JAK2, which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation, and subsequent localization of STATs to the nucleus leading to modulation of gene expression. MF and PV are myeloproliferative neoplasms (MPNs) known to be associated with dysregulated JAK1 and JAK2 signaling. In a mouse model of...
Therapeutic areas: Oncology · Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
5 products under this application
- JAKAFI XR · RUXOLITINIB PHOSPHATE EQ 44MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
- JAKAFI XR · RUXOLITINIB PHOSPHATE EQ 22MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
- JAKAFI XR · RUXOLITINIB PHOSPHATE EQ 55MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
- JAKAFI XR · RUXOLITINIB PHOSPHATE EQ 33MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
- JAKAFI XR · RUXOLITINIB PHOSPHATE EQ 11MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ruxolitinib" as an intervention, any sponsor and status, largest first.
- INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01493414 · 2,233 participants · Start Aug 16, 2011 · Primary completion Jan 26, 2017
Drug: INC424 · For: Myelofibrosis
Sites: Algiers, Algeria; CABA, Argentina; Paraná, Argentina · 273 sites in all
- Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALLPivotal-lookingRecruiting
Bambino Gesù Hospital and Research InstituteAcademic, hospital or other
NCT07297914 · 1,000 participants (planned) · Start Jan 7, 2026 · Primary completion Nov 30, 2032
Drug: Blinatumomab; Cyclophosphamide and 1 more · For: Acute Lymphoblastic Leukemia (ALL); Stem Cell Transplant; Graft -Versus-host-disease
Sites: Vienna, Austria; Prague, Czechia; Copenhagen, Denmark · 9 sites in all
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaPivotal-lookingActive, not recruiting
St. Jude Children's Research HospitalAcademic, hospital or other
NCT03117751 · 790 participants · Start Mar 29, 2017 · Primary completion Sep 30, 2026
Drug: Prednisone; Vincristine and 21 more · For: Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma
Sites: Palo Alto, California; San Diego, California; Peoria, Illinois · 8 sites in all
- Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic DermatitisPivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT03745638 · 631 participants · Start Dec 20, 2018 · Primary completion Dec 23, 2019
Drug: Ruxolitinib Cream; Vehicle Cream · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Fountain Valley, California · 79 sites in all
- TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic DermatitisPivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT03745651 · 618 participants · Start Dec 20, 2018 · Primary completion Nov 18, 2019
Drug: Ruxolitinib cream; Vehicle cream · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Fremont, California; Huntington Beach, California · 66 sites in all
- Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to RuxolitinibPivotal-lookingRecruiting
Kartos Therapeutics, Inc.Industry
NCT06479135 · 600 participants (planned) · Start Jun 3, 2024 · Primary completion Dec 31, 2026
Drug: Navtemadlin; Navtemadlin placebo and 1 more · For: Myelofibrosis; Post-PV MF; Post-ET Myelofibrosis and 2 more
Sites: Birmingham, Alabama; Gilbert, Arizona; Phoenix, Arizona · 215 sites in all
- MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia VeraPivotal-lookingRecruiting
University of BirminghamAcademic, hospital or other
NCT04116502 · 586 participants (planned) · Start Oct 25, 2019 · Primary completion Oct 31, 2028
Drug: Ruxolitinib; Hydroxycarbamide and 1 more · For: Polycythemia Vera
Sites: Aberdeen, United Kingdom; Bath, United Kingdom; Belfast, United Kingdom · 55 sites in all
- Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)Pivotal-lookingActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT06959225 · 580 participants · Start Jun 23, 2025 · Primary completion Oct 29, 2026
Drug: Ruxolitinib Cream; Vehicle Cream · For: Hidradenitis Suppurativa
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tempe, Arizona · 101 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,418
- drug ineffective1,035
- death787
- product use in unapproved indication781
- anaemia738
- pyrexia597
- pneumonia578
- thrombocytopenia562
- platelet count decreased532
- haemoglobin decreased511
- febrile neutropenia458
- splenomegaly446
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 11 |
| 2013 | 14 |
| 2014 | 22 |
| 2015 | 53 |
| 2016 | 103 |
| 2017 | 209 |
| 2018 | 299 |
| 2019 | 333 |
| 2020 | 528 |
| 2021 | 1,104 |
| 2022 | 1,650 |
| 2023 | 1,844 |
| 2024 | 1,599 |
| 2025 | 1,653 |
| 2026 | 1,275 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Immune Checkpoint Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis.
Nielsen DL, Juhl CB, Nielsen OH, et al. · JAMA Oncol 2024 · Systematic Review, Meta-Analysis
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Mesa RA, Kiladjian JJ, Catalano JV, et al. · J Clin Oncol 2017 · Clinical Trial, Phase III, Comparative Study
- Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
Rosmarin D, Passeron T, Pandya AG, et al. · N Engl J Med 2022 · Clinical Trial
- Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu DK, Chu AWL, Rayner DG, et al. · J Allergy Clin Immunol 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
Zeiser R, von Bubnoff N, Butler J, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Corticosteroid-resistant immune-related adverse events: a systematic review.
Daetwyler E, Wallrabenstein T, König D, et al. · J Immunother Cancer 2024 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Incyte
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.